JEFF ARONIN: LEADING BIOSCIENCES INTO THE FUTURE

Jeff Aronin serves as the chief executive officer and chairman of Paragon Biosciences, a healthcare development and bio pharmaceutical investment firm based in Chicago, Illinois since 2010. In the world of bioscience investments, Jeff Aronin is one of the top players on the stage. His vision and strategic management have made Paragon Biosciences a tremendous force in the scope of medical investments.

Paragon is not Jeff’s first rodeo, however. Jeff has been involved as founder, co-founder, and chief executive officers of Castle Creek Pharmaceuticals, Ovation Pharmaceuticals, and has served as a consistent lecturer at the esteemed University of Chicago Booth School of Business. His aspirations is displayed through his history of leadership and innovation.

The most recent endeavor is MATTER, a group of investors in Chicago working to solve the challenges of healthcare and healthcare investment. The mission of MATTER is to help all stages of growth in a startup company solving issues surrounding healthcare, developing a synergy of respected health systems as well as executives to learn from each other and ultimately, help businesses thrive on challenge becoming more successful.

MATTER promises to bring an innovative approach to bio medical sciences which is the wheelhouse of Jeff and his team of investors.

Is Jeff Aronin taking the medical investment world by storm? It would indeed seem so through his ventures and notoriety. Recently, Jeff was recognized for his efforts by Insights Care magazine as one of the 20 Most Influential Leaders in Healthcare for 2018. Jeff has followed key principles in leadership, recruiting and retaining a highly skilled professional team that shares his vision for the future of biomedical sciences.

Jeff Aronin continuously raises the bar in biomedical investments and development. Starting out as a motivated investor throughout the Midwest, he has taken his leadership and integrity world wide, focusing on those businesses that promise a new horizon in biomedical sciences.

read more about jeff aronin below

https://www.paragonbiosci.com/news/2018/10/19/paragon-biosciences-announces-718-million-in-new-investment-for-portfolio-company-castle-creek-pharma